Serotonin-Related Psychedelic Drugs ☆
Elsevier eBooks January 1, 2017 Mark A. Geyer, David E. Nichols, Franz X. Vollenweider 5 citations
No Summary
David E. Nichols
GTx (United States)
31 papers in the library · 2,103 citations · publishing 1977-2023
Papers
ChemInform Abstract: Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O‐Acetyl Prodrug of Psilocin.
ChemInform August 17, 1999 David E. Nichols, Steward Frescas 2 citations
The text describes ChemInform, a weekly abstracting service that extracts concise information from about 100 leading journals. It explains how to access the full abstract of an article published elsewhere and how to track the original article via references.
Remove barriers to clinical research for schedule 1 drugs with therapeutic potential
BMJ May 2, 2023 Leslie A. King, David Nutt, David E. Nichols 1 citation
The authors argue that regulations governing clinical research on Schedule 1 drugs, which are classified as having high abuse potential and no accepted medical use, should be reassessed. They contend that such classification unnecessarily impedes scientific investigation into substances with therapeutic potential, such as certain psychedelics. The piece advocates for a review of the scheduling system to facilitate research that could lead to medical treatments, while maintaining appropriate controls to prevent misuse.
trans -2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans -2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT 2 receptor family
UNC Libraries October 31, 2020 Adam Pigott, Bryan L. Roth, Xi‐ping Huang et al.
Replacing the ethylamine side chain of the psychedelic compounds DOI and DOB with a cyclopropylamine group produced new molecules that bind strongly to 5-HT2 family serotonin receptors. The most potent version had the (−)-(1R,2S)-configuration. However, these cyclopropane analogs also showed increased affinity for other serotonin receptor subtypes beyond 5-HT2A and 5-HT2B, making them less selective than the original compounds. At appropriate doses, they may serve as research tools for studying 5-HT2 receptor function, but their reduced selectivity for 5-HT2A receptors must be considered.
Psychedelics
UNC Libraries April 22, 2020 David E. Nichols
Psychedelics are psychoactive substances that alter perception, mood, and cognition, are physiologically safe, and do not cause addiction. They act as agonists at brain serotonin 5-HT2A receptors, especially on layer V neocortical pyramidal cells. Recent double-blind placebo-controlled phase 2 studies of psilocybin-assisted psychotherapy in patients with cancer-related psychosocial distress showed unprecedented relief of anxiety and depression. Two small pilot studies also showed positive benefits for alcohol and nicotine addiction. Imaging after intravenous psilocybin and LSD revealed decreased oscillatory power in the brain's default mode network.
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
Journal of Psychopharmacology July 14, 2019 Livia Ng, Luca Pani, Anaïs Soula et al.
Claims about the positive effects of microdosing psychedelics on mood and cognition have entered public discussion, but scientific studies are scarce and no consensus on what microdosing means exists. This critique identifies questions future research must answer and offers guidelines, focusing on psilocybin due to its potential clinical approval and short-lasting effects. While anecdotal reports emphasize benefits, the paper concludes that future studies should also investigate potential risks of repeated low-dose administrations. Preclinical and clinical research examining biological measures like heart rate and receptor turnover, as well as cognitive parameters such as memory and attention, is needed to uncover possible negative consequences.